Adma Biologics price to free cash flow ADMA

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Oct 23, 2026: 20.5×
3-year median: 56.9×
Against its 3-year history: 17th; percentile: 0 is its lowest day, 100 its highest
3-year range: 17.1× to 386×
Peer median: 35.3×

Adma Biologics' price to free cash flow is 20.5× as of Oct 23, 2026.

That is below its 3-year median of 56.9×, lower than on 83% of days in the last 3 years.

Over that time it ranged from 17.1× in Jun 2026 to 386× in May 2024.

The median for 9 biotech stocks of a similar size is 35.3×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	20.5×	17.1×	133×
2025	113×	38.7×	116×
2024	52.0×	51.8×	386×

Against its peers

Companies in Biotechnology nearest Adma Biologics' size, closest first, today.

Company	Price to free cash flow
ADMAAdma Biologics	20.5×
VCELVericel	35.3×
MGTXMeiraGTx	84.5×
KRYSKrystal Biotech	35.8×
RGENRepligen	89.2×
TECHBIO-TECHNE	43.2×
HALOHalozyme Therapeutics	17.7×
NBIXNeurocrine Biosciences	16.7×
EXELExelixis	13.6×
INCYIncyte	12.2×
Peer median	35.3×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Adma Biologics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.